Company intelligence

HCM

HUTCHMED (China) Limited · NASDAQ · Healthcare

Price$12.26+0.66% · +$0.08

Market cap2.14BEquity value

P / E4.6Trailing ratio

Volume73.56KLatest session

Market data

HCM price chart

TradingView

Related signals

1 min delayed

Browse public HCM signals with their source context and measured market impact. Open any signal for its permanent analysis page.

HCMJan 7, 2026+4.02% since signal

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

HUTCHMED's trial for sovleplenib in wAIHA met primary healing endpoints. Annual incidence rate of wAIHA is estimated at 0.8-3.0 per 100,000 adults. Sovleplenib shows overall response rates of 43.8% and 66.7% in studies. New Drug Application submission for sovleplenib is planned for mid-2026. HUTCHMED shares rose 5.09% to $14.45 during premarket trading.

View signal analysis

HCMMar 19, 2025-1.04% since signal

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

HCM's Q4 earnings dropped to 22 cents per ADS, down from 59 cents. Sales fell 25% YoY to $630.20 million; oncology revenue rose 65%. Guidance for 2025 oncology/immunology revenue projected at $350M-$450M. Fruquintinib/sintilimab treatment met primary survival endpoint in trials. Stock price rose 8.7% to $16.26 following announcements.

View signal analysis

Research